The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.” 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account